In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
How a group of Buddhist monks bought up a chunk of PEI
Ukrainian refugees fled to Poland. Now thousands are leaving
Can a 4 billion year-old asteroid reveal the origins of life?
A Dollarama executive, a luxury home and a World Heritage site
Why it’s so hard to bring food prices down
Will 3.45 million new homes solve Canada’s housing crisis?
What’s behind the delays in Canada’s courts?
Introducing: In Her Defence, a new true crime podcast
The view from India after allegations of killing in Canada
Your Ontario Greenbelt questions, answered
Trudeau accuses India of involvement in Canadian’s murder
Coup contagion – why Africa’s had nine coups in three years
A Trudeau-Poilievre showdown as Parliament resumes
Lessons from the massive daycare E.Coli outbreak in Calgary
A multi-billion dollar bet on natural gas
What you need to know about COVID this fall
Australia resolved its news standoff with Meta. Could Canada?
The first criminal trial for ‘Freedom Convoy’ leaders
How international students became big business for schools
Canada’s wildfires dwarf emissions from all other industries
Create your
podcast in
minutes
It is Free
As It Happens
The Daily
Morning Wire
Up First
Dobré ráno | Denný podcast denníka SME